BeiGene (ONC) said Tuesday the US Food and Drug Administration approved Tevimbra, in combination with platinum-containing chemotherapy, for the first-line treatment of certain adults with unresectable or metastatic esophageal squamous cell carcinoma.
The company said the approval is based on a phase 3 study where Tevimbra combination therapy showed a statistically significant improvement in overall survival.
Tevimbra is also approved in the US as monotherapy for some patients with esophageal squamous cell carcinoma and in combination with chemotherapy for the first-line treatment of adults with gastric and gastroesophageal junction cancers, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.